close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

158.91 +4.77 (+3.09%)
Streaming Delayed Price Updated: 12:57 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
News headline image
3 European Stocks to Carry Investors Through the Back Half of 2026 ↗
European stocks are outpacing the S&P 500 in 2026, and ArcelorMittal, Arm Holdings, and Novartis are three Euro Stoxx 50 components with index-beating returns. 
Via MarketBeat
Topics ETFs Stocks
News headline image
Core Restore Founder Ann Peets Announces Bladder Leak Treatments In Charleston
Via Press Release Distribution Service
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal ↗
Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers. 
Via Benzinga
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years ↗
International stocks are trading for a steep discount, and here's a great way to invest. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum. 
Via The Motley Fool
News headline image
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study ↗
Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy. 
Via Benzinga
News headline image
IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗
When buying international ETFs, owning more stocks in more countries might be a better bet. 
Via The Motley Fool
Topics ETFs
News headline image
VXUS Has Delivered Better Returns Than IEFA Over the Past 5 Years. Should It Be in Your Portfolio? ↗
The Vanguard Total International Stock ETF's (VXUS) outperformance stems from where it invests. 
Via The Motley Fool
Topics ETFs
News headline image
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer... 
Via MarketBeat
News headline image
IEFA: Why This Fund Is One of the Best International ETFs ↗
Yesterday's slow-growing economies might be tomorrow's best places to invest. 
Via The Motley Fool
Topics ETFs
News headline image
Dry eye syndrome drugs Market Size, Industry Report By 2035 ↗
The most recent research report on the "Dry eye syndrome drugs Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic foreca 
Via Talk Markets
Topics Economy
News headline image
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns. ↗
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story. 
Via The Motley Fool
Topics ETFs
News headline image
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗
This little-discussed pipeline program could prove to be a big success. 
Via The Motley Fool
News headline image
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem ↗
A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles. 
Via The Motley Fool
Topics ETFs
News headline image
Pediatrics Medicine Market Size, Industry Report By 2035 ↗
The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts 
Via Talk Markets
Topics Economy
News headline image
3 International ETFs for Investors Looking Beyond U.S. Stocks ↗
These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗
With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk. 
Via MarketBeat
Topics Credit Cards ETFs Economy
News headline image
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across... 
Via MarketBeat
News headline image
PTCT Q1 2026 Earnings Transcript ↗
PTCT Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout ↗
The biotech stock skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment. 
Via Investor's Business Daily
News headline image
Incyte (INCY) Q2 2025 Earnings Transcript ↗
Incyte (INCY) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Novartis Dips As Generics Take A Bite Out Of Its First-Quarter Sales ↗
Novartis stock fell early Tuesday on lighter-than-expected first-quarter earnings and sales amid U.S. generic erosion. 
Via Investor's Business Daily
News headline image
Better Pharma Dividend Stock: Novartis vs. Merck ↗
Both are great stocks to buy in the current environment, but which one is the better bet? 
Via The Motley Fool
Topics Intellectual Property
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today